Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitamin C supplementation, alone or in combination with allopurinol, appears to have a weak effect on lowering uric acid levels in gout patients according to the results published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism.
[More]
Novartis announced today that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.
[More]
BioCryst Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2013.
[More]
A new study led by researchers at the Graduate Entry Medical School (GEMS), University of Limerick (UL) has found that people suffering from gout and elevated serum uric acid have significantly increased risks of death.
[More]
Rheumatoid arthritis (RA) is an autoimmune disorder that can cause debilitating joint damage. In cases of RA, the immune system attacks the body’s own tissues, especially the membranes that line the joints. As a result, fluid builds up in the joints, causing pain and systemic inflammation, leading to joint destruction if untreated.
[More]
According to a study published in the Journals of Gerontology Series A: Biological Sciences and Medical Sciences, a baseline adherence to a Mediterranean diet (MeDiet) is associated with a lower risk of hyperuricemia, defined as a serum uric acid (SUA) concentration higher than 7mg/dl in men and higher than 6mg/dl in women.
[More]
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced the availability of two new blood tests for aiding the early diagnosis of arthritis (RA), an autoimmune disorder that can cause debilitating joint damage.
[More]
Johns Hopkins scientists have found out how a gout-linked genetic mutation contributes to the disease: by causing a breakdown in a cellular pump that clears an acidic waste product from the bloodstream.
[More]
BioCryst Pharmaceuticals, Inc. today announced that it received a preliminary comment letter from the U.S. Food & Drug Administration that outlines a pathway by which BioCryst could file a New Drug Application seeking regulatory approval of intravenous (i.v.) peramivir.
[More]
BioCryst Pharmaceuticals, Inc. today announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers.
[More]
Findings from a Loyola University Chicago Stritch School of Medicine study could lead to the development of new drugs to treat gout.
[More]
BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2012.
[More]
Reportlinker.com announces that a new market research report is available in its catalogue: Global Ophthalmic Instrumentation Industry
[More]
Rheumatoid arthritis patients can develop gout, say researchers who believe changes in treatment and obesity may explain why the comorbidity is now occurring.
[More]
A vasopressin V2-receptor blocker slows the increase in total kidney volume and decline in kidney function in patients with autosomal dominant polycystic kidney disease, report US researchers.
[More]
BioCryst Pharmaceuticals, Inc. today announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
[More]
BioCryst Pharmaceuticals, Inc. today announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).
[More]
More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.
[More]
Savient Pharmaceuticals, Inc. and its wholly owned subsidiary, Savient Pharma Ireland Limited, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has completed its scientific assessment and has issued a positive opinion recommending approval of a marketing authorization in the European Union for KRYSTEXXA for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.
[More]
Gout is one of the most common forms of inflammatory arthritis, affecting nearly 4% of adult Americans. Newly approved guidelines that educate patients in effective methods to prevent gout attacks and provide physicians with recommended therapies for long-term management of this painful disease are published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR).
[More]